BTIG Maintains Buy on Haemonetics, Raises Price Target to $130

Benzinga Newsdesk www.benzinga.com Positive 82.7%

Neg 0% Neu 0% Pos 82.7%

BTIG analyst Marie Thibault maintains Haemonetics (NYSE:HAE) with a Buy and raises the price target from $110 to $130.

Comments

No comments yet. Be the first!